Amyvid Recommended for Approval in Europe

by Benzinga Staff
October 19, 2012 10:56 AM | 26 seconds read

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Eli Lilly and Company (NYSE: LLY)and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, todayannounced they received a positive opinion from the Committee for MedicinalProducts for Human Use (CHMP) in Europe, recommending approval of Amyvid(Florbetapir F 18) solution for injection as a diagnostic radiopharmaceuticalindicated for Positron Emission Tomography (PET) imaging of beta-amyloidneuritic plaque density in the brains of adult patients with cognitiveimpairment who are being evaluated for Alzheimer's Disease and other causes ofcognitive impairment. Amyvid should be used in conjunction with a clinicalevaluation.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.